Vaccine Breakthrough Stops Cancer Returning in Trial The latest trial results from Merck and Moderna's collaborative vaccine project have sent shockwaves through the medical community.
A personalized vaccine, called Intismeran, has shown promise in halting the return of cancer in patients with high risk melanoma when used in combination with Keytruda, an immunotherapy drug already in use.
The significance of this trial lies not just in its findings but also in the technology behind it.